GlassScriptPhysician profile
Leon Robert Shein
NPI 1215004858
$17,195.50
in general payments reported to CMS, 2019-2025
23 companies · $14K in 2025
The $14K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $276 · 2021: $534 · 2022: $724 · 2023: $348 · 2024: $928 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $2,393 · Travel and Lodging: $1,093 · Education: $38.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,395.00 |
| Food and Beverage | $2,393.02 |
| Travel and Lodging | $1,092.70 |
| Education | $38.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $13,456.16 | 2020-2025 | Vafseo, Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $764.46 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $602.05 | 2019-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $580.72 | 2019-2024 | Lokelma, Farxiga |
| Glaxosmithkline, LLC. | $296.93 | 2020-2022 | |
| Mallinckrodt Enterprises LLC | $179.85 | 2019 | |
| Vifor Pharma, INC. | $178.73 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $158.95 | 2019-2023 | Jynarque |
| Lilly USA, LLC | $141.29 | 2021-2024 | Mounjaro |
| Ardelyx, INC. | $138.13 | 2024-2025 | Ibsrela |
| Genentech USA, INC. | $136.05 | 2019 | |
| Amgen INC. | $98.60 | 2019-2022 | |
| Shire North American Group INC | $86.98 | 2019 | |
| Mallinckrodt Hospital Products INC. | $73.24 | 2022 | |
| Travere Therapeutics, INC. | $67.91 | 2021-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $63.74 | 2024 | |
| Opko Pharmaceuticals, LLC | $54.24 | 2019-2023 | Rayaldee |
| Ibsa Pharma INC. | $24.98 | 2024 | Tirosint, Licart |
| Cormedix INC. | $22.13 | 2025 | Defencath |
| Novo Nordisk INC | $19.70 | 2020 | |
| Aurinia Pharma U.S., INC. | $18.64 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.13 | 2024 | Gattex |
| Merck Sharp & Dohme LLC | $14.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Shein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.